Colin Stott

Colin Stott is the COO of Phytanix Bio. He is the former Research & Operations Director (from 2001 to 2017) and International Scientific Affairs Director of GW Pharmaceuticals (from 2017 to 2019) and was closely involved in the development and approval of the cannabinoid medicines Sativex® and Epidiolex® / Epidyolex®. Colin is a named inventor on 17 GW Pharmaceuticals / GW Research Ltd patents and has more than 25 publications in the cannabinoid sector. He is an independent director on the Board of Directors of Cardiol Therapeutics Inc., a company developing cannabidiol for the treatment of cardiac disorders.